The outcomes of patients who experience the failure to reconstitute a trilineage of blood cells after initial neutrophil engraftment were evaluated in 178 patients with hematologic disorders, who underwent allogeneic HCT. Of 165 qualified patients (five with primary engraftment failure; eight deaths before day 60 of HCT), 43 (26%) satisfied the criteria for the initial (n ¼ 22; failure of platelet 420 000/ll or red blood cell transfusion independence/reticulocyte count X1.0% by day 60) or subsequent (n ¼ 21, ANC o500/ll for X3 days, platelet o20 000/ll for X7 days, or red blood cells transfusion/reticulocyte o1.0% after initial trilineage reconstitution) failure. GVHD was the most common clinical condition associated with cytopenia (n ¼ 24). In all, 20 patients (47%) recovered at least partially with a median of 52 days (range 8-323) later, with 12 of those 20 patients recovering completely. The eventual reconstitution failure rate was 14% (23/163 patients). The number of cell lineages involved in the cytopenia was the only independent variable that predicted partial recovery (1 lineage vs 2-3 lineages with odds ratio of 8.69 (95% CI 1.96-38.60), P ¼ 0.004). Five/20 patients with vs 20/23 patients without partial recovery died. Trilineage reconstitution failures after allogeneic HCT need systematic analysis in the future studies.
bone marrow reconstitution; trilineage reconstitution failure Successful allogeneic hematopoietic cell transplantation (HCT) requires the eradication of the underlying disease of the patient and engraftment of the patient's bone marrow with donor hematopoietic cells, with a subsequent reconstitution of the trilineage of the blood cells. 1 However, delayed reconstitution of donor cells as well as transient or permanent cytopenia after initial trilineage reconstitution is commonly observed after allogeneic HCT. A multitude of pre-and post transplantation factors may play a role, alone or in combination, in the failure to maintain the three lineages of blood cells and include immunologically mediated graft rejection, [2] [3] [4] [5] [6] poor graft function including T-cell depletion, [5] [6] [7] moderate-to-severe hepatic veno-occlusive disease (VOD), 8 acute and chronic graft-versus-host disease (GVHD), 9 viral infections, 10 sepsis, hypersplenism, and myelosuppressive drugs. Any measures introduced to decrease post transplant cytopenia may actually increase the overall incidence of trilineage reconstitution failure due to unexpected contributing factors, and consequently increase the morbidity and mortality of patients. For example, an increased intensity of the conditioning regimen to decrease graft failure may actually increase the overall incidence of reconstitution failure due to increased regimen-related toxicities. Systematic evaluation of the overall population of patients with trilineage reconstitution failure may be necessary to improve the overall effectiveness of any given method of allogeneic HCT.
This study was conducted: (1) to investigate the frequency and outcome of failure of trilineage reconstitution after allogeneic HCT, and (2) to identify factors, which might predict the eventual outcome of cytopenia and the survival of patients.
Patients and methods

Patients and transplantation procedure
Between January 1998 and September 2002, 178 consecutive adult patients with various malignant and nonmalignant hematologic disorders underwent allogeneic HCT at the University of Ulsan, Asan Medical Center in Seoul, Korea, and were included in the study. Various pre-and post transplant clinical data were retrieved from our BMT database. We also retrospectively reviewed the medical record and laboratory data of each patient. Five patients failed to achieve an initial ANC 4500/ml, and died between day 19 and 106 after allogeneic HCT (median day 33). Eight patients achieved ANC 4500/ml between days 8 and 26 after HCT, but died within 60 days of HCT due to acute GVHD (n ¼ 5), interstitial pneumonia (n ¼ 2), and CNS bleeding, thus leaving 165 patients for the evaluation. Eight patients, who showed delayed red blood cell reconstitution, which was clearly related to residual recipient isoagglutinin against donor red blood cells, were diagnosed to have pure red cell aplasia, 11 and were excluded from the analysis of initial failure, but included in the analysis of subsequent failure. The study protocols for specific conditioning regimens were approved by the Institutional Review Board. Written informed consents were obtained from the patients and donors. Patients with malignant hematologic disorders, including myelodysplastic syndrome (MDS), received a BuCy regimen (busulfan 4 mg/kg/day orally on days À7 to À4 and cyclophosphamide 60 mg/kg/day by intravenous infusion on days À3 to À2) for conditioning therapy. 12 Beginning on July 1999, a nonmyeloablative conditioning regimen of Bu-Flu-ATG (busulfan 4 mg/kg/day orally on days À7 and À6, fludarabine (Fludara, Berlex Laboratories, Richmond, CA, USA) 30 mg/m 2 /day by intravenous infusion on days À7 to À2, equine antithymocyte globulin (Atgam, Upjohn, Kalamazoo, MI, USA ) 10-20 mg/kg/day by intravenous infusion on days À5 to À2, and methylprednisolone 2 mg/kg/day by intravenous infusion on days À5 to À2) was given to patients with acute leukemia, who were elderly or who had comorbidity, and patients with low-risk MDS or paroxysmal nocturnal hemoglobinuria (PNH). 13 Intravenous busulfan (Busulfex, Orphan Medical, Minnetonka, MN, USA) 3.2 mg/kg/day has replaced the daily oral dose of busulfan since August 2002. Patients with severe aplastic anemia (SAA) received Cy-ATG regimen (cyclophosphamide 50 mg/kg/day by intravenous infusion on days À5 to À2 and Atgam 30 mg/kg/day by intravenous infusion on days À4 to À2). HLA matching for donor selection was based on serologic typing for HLA A, B, and C antigens (Terasaki Oriental HLA (72) Well Tray, Lot #23A, One Lambda Inc., Canoga Park, CA, USA) and a molecular typing for HLA-DRB1 antigen (LiPA HLA-DRB1, Innogenetics, Gent, Belgium). For unrelated donors, six antigens of HLA A, B, and DRB1 were considered. Patients who were conditioned with the BuFlu-ATG regimen received granulocyte colony-stimulating factor-mobilized peripheral blood hematopoietic cells (G-CSF, 10 mg/kg/day subcutaneously for 4 days) on days 0 and 1. None of the hematopoietic cell grafts were T-cell depleted. The regimen for the prophylaxis of GVHD consisted of cyclosporine 1.5 mg/kg by intravenous infusion every 12 h starting on day À1, which was then switched to an oral dose when oral intake became feasible. Cyclosporine levels were monitored weekly with a reference blood level of 100À300 ng/ml. In addition to cyclosporine, patients received a short course of methotrexate. Those patients who were included in a randomized trial comparing cyclosporine plus methotrexate vs cyclosporine alone for the GVHD prophylaxis, and who were assigned to the cyclosporine alone arm, did not receive methotrexate. All patients received a daily dose of G-CSF 450 mg intravenously, starting on day 0 or day 5 of infusion of donor hematopoietic cells until the peripheral blood absolute neutrophil count (ANC) was over 3000/ml. The same dose of G-CSF was administered daily when ANC decreased below 1000/ml and continued until ANC recovered to 3000/ml.
Complete blood counts including reticulocyte count (CBC) were done daily in all patients while they were in the hospital, and on each visit to the outpatient clinic. All patients were monitored prospectively for the occurrence of adverse events, including GVHD, regimen-related toxicities, and infections. Acute and chronic GVHD were classified according to the criteria of Przepiorka et al 14 and Sullivan et al, 15 respectively. A diagnosis of VOD was made according to the clinical criteria of McDonald et al. 16 Hematopoietic chimerism was analyzed from peripheral blood samples monthly for 3 months and then every 3 months for 2 years after allogeneic HCT. When patients had significant cytopenia, chimerism assay was repeated. A polymerase chain reaction (PCR)-based procedure utilizing short tandem repeats of DNA was used. The detailed methods of PCR analysis have been described previously. 17 
Definitions of failure of trilineage blood cell reconstitution
Patients were considered to have an initial failure to constitute a trilineage of blood cells, when at least one of the following was present without evidence of relapse of leukemia after the initial achievement of peripheral blood ANC 4500/ml after HCT: (a) failure to achieve platelet 420 000/ml by day 60, and (b) failure to achieve red blood cell transfusion independence and uncorrected reticulocyte count X1.0% by day 60. Patients were considered to have subsequent failure to maintain trilineage reconstitution when at least one of the following was present without evidence of relapse of leukemia after initial achievement of trilineage reconstitution of ANC 4500/ml, platelet 420 000/ml, and red blood cell transfusion independence: (a) ANCo500/ml for at least 3 consecutive days, (b) platelet o20 000/ml for at least 7 consecutive days, and (c) requirement of red blood cell transfusion with uncorrected reticulocyte count o1.0%.
Definitions of partial and complete recoveries
The criteria for a partial recovery from the failure of trilineage blood cell reconstitution were defined as follows: in cases of failure of a single lineage, improvement of that lineage to the following degree (hemoglobin þ 2 g/dl, ANC þ 500/ml, or platelet þ 20 000/ml). In cases with failure of multiple lineages, (a) the absence of the need for transfusions and (b) at least one lineage recovered from the criteria of failed reconstitution to the above criteria. Complete recovery was defined as normalization of all the three lineages of cells (hemoglobin 412 g/dl, ANC 43000/ ml, and platelet 4100 000/ml).
Statistical analysis
Categorical variables were compared using a w 2 test. A continuous variable (patient age) was compared using the Mann-Whitney U-test. For the prediction of partial and complete recoveries in patients with reconstitution failure, the individual characteristics were analyzed using the w 2 test. Variables with a P-value less than 0.1 by univariate Failure of trilineage reconstitution after allogeneic HCT K-H Lee et al analysis, along with the age and sex of patients, were considered for entry into a subsequent multivariate analysis using the multiple logistic regression model. The times to recovery and patient survival were calculated from day 60 of HCT (initial failure) or from the first day of documented cytopenia (subsequent failure). Patients who recurred with underlying leukemia or who were treated with donor leukocyte infusion (DLI) for cytopenia were censored at the time of recurrence or DLI, respectively.
Results
Frequency of failure of trilineage reconstitution
The characteristics of 165 qualified patients, with or without reconstitution failure, are presented in Table 1 . In all, 43 patients (26%) satisfied the criteria for the failure to reconstitute trilineage blood cells (22 with initial failure; 21 with subsequent failure). The median ages of the patients were 30 years (range 17-48) and 27 years (17-47) for initial and subsequent failure, respectively. Patients who underwent unrelated HCT were more likely to experience reconstitution failure. A higher proportion of patients with reconstitution failure showed a positive test for CMV culture or antigenemia, and received pre-emptive therapy with ganciclovir. In all, 12 of 22 patients with initial failure and seven of 21 patients with subsequent failure received hematopoietic cells from matched unrelated donors. Of 22 patients with initial failure, 12 showed failure in a single lineage (six each with platelet failure and red blood cell failure), while the rest showed failure in both platelet and red blood cell reconstitution. In patients with subsequent failure, 11 showed failure in a single lineage (five with platelet, four with neutrophil, and two with red blood cell failure), six showed in two lineages (five with platelet þ red blood cells, one with neutrophil þ platelet), and four showed in all the three lineages. The median onset of cytopenia in patients who experienced subsequent failure was day 66 after HCT (range 35-481).
Clinical conditions that coexisted with the failure of trilineage reconstitution
The most common clinical condition that coexisted with trilineage reconstitution failure was grade II-IV acute GVHD (13 of 22 initial failures and seven of 21 subsequent failures). Four patients with subsequent failure had an extensive stage chronic GVHD. Hematopoietic chimerism was assayed in 22 of 24 patients with GVHD-associated reconstitution failure on day 60 of HCT (one patient showed complete chimerism on day 30, but had no extractable DNA on day 60) and 21 patients showed complete donor chimerism (CC). One patient showed a low degree of mixed chimerism of 5% recipient DNA.
The other clinical conditions that coexisted with reconstitution failure were cytomegalovirus (CMV) antigenemia with treatment with ganciclovir (n ¼ 4), multiorgan failure with active infection (n ¼ 2), splenomegaly (n ¼ 1), and thrombotic thrombocytopenic purpura (TTP)-like syndrome with leukoencephalopathy (n ¼ 1). In all, 11 patients did not have any identifiable clinical condition that could explain the cause of cytopenia. Seven out of 10 evaluable patients without identifiable clinical conditions showed mixed chimerism with recipient DNA ranging from 5 to 75%, upon hematopoietic chimerism assay.
Outcome of failure of trilineage reconstitution
Out of 43 patients, 20 (47%) recovered at least partially 8-323 days after the initial documentation of reconstitution failure (median 52 days), and 12 of those 20 patients recovered completely 120-938 days after the initial documentation of reconstitution failure (median 263 days, Figure 1 ). In all, 23 patients failed to recover eventually, with an overall reconstitution failure rate of 14% (23/163 patients). Table 2 shows the various pre-and post transplant characteristics that might have an effect on the outcome of reconstitution failure. Patients who were transplanted from sibling donors had a higher likelihood of partial recovery when compared to patients who were transplanted from unrelated donors (P ¼ 0.017). Patients with reconstitution failure in a single lineage of cells were more likely to recover when compared to patients with failure in two or three lineages of cells (P ¼ 0.001). When these two variables were considered for multivariate analysis along with the age and sex of the patients, the number of involved lineages was the only independent variable that showed a predictive value for the likelihood of partial recovery (one lineage vs two to three lineages with an odds ratio of 8.69 (95% CI 1.96-38.60), P ¼ 0.004).
Of 11 patients without identifiable clinical conditions that could explain the cause of the cytopenia, five patients recovered at least partially 8-56 days later (median 31 days), with rapid withdrawal of the immunosuppressive agent given for the prophylaxis of GVHD. Three of these five patients showed an MC of recipient DNA of 5-45% at the time of cytopenia, which converted to CC upon partial hematologic recovery. Five patients received DLI, but none responded. All the four patients who were under ganciclovir treatment for CMV antigenemia at the onset of cytopenia without evidence of GVHD recovered at least partially 26-84 days later (median 58 days).
The median survival time of all 43 patients was 279 days (range 2-1375 þ ) after the onset of cytopenia. After a median follow-up of the surviving patients of 814 days (range 172-1375), 20 of 23 patients who did not recover from the cytopenia died within 2-570 days (median 68 days) after initial documentation of the trilineage reconstitution failure. The causes of death were acute GVHDrelated complications (n ¼ 7), chronic GVHD-related complications (n ¼ 5), VOD and subsequent multiorgan failure (n ¼ 2), bacterial sepsis (n ¼ 4; despite DLI 13-67 days after initial documentation of failure), and idiopathic interstitial pneumonia (n ¼ 2). The outcome of three surviving patients was autologous reconstitution of CML clone and treatment with gleevec (n ¼ 1), autologous recovery from SAA (n ¼ 1), and partial recovery after DLI (n ¼ 1). Five of 20 patients who recovered partially died due to leukemia relapse (n ¼ 3), peumococcal sepsis (n ¼ 1), and respiratory failure due to bronchiolitis obliterans (n ¼ 1). 
Discussion
The aim of our study was to define the overall frequency and outcome of the failure to reconstitute trilineage of blood cells after allogeneic HCT. The criteria of cytopenia used in our study were similar to those used in patients with SAA. 18 The criteria for the recovery of cytopenia were also similar to those of recovery of SAA by the SAA Working Party of the EBMT, except for the criteria of recovery of hemoglobin, which was modified to 2 g/dl instead of 3 g/ dl. 19 To our knowledge, a systematic analysis of the overall population of patients with cytopenia in single or multiple lineages of blood cells after allogeneic HCT has not been reported in the literature.
Our study showed that, after allogeneic HCT, a significant proportion of patients (26%) experienced difficulty in the establishment or maintenance of a trilineage of peripheral blood cells after initial engraftment of neutrophils with significant life-threatening cytopenia. Obviously, the cause of failure of trilineage reconstitution after allogeneic HCT is multifactorial in most cases, and cannot be determined with certainty in individual cases. However, the majority of our patients had clinical conditions that could explain the cause of cytopenia, such as GVHD, multiorgan failure with active infection, and administration of medications with myelosuppressive effects. Out of 43 patients with trilineage reconstitution failure in our series, 11 (26%) had no evidence of GVHD or of active infection, and were not on any myelosuppressive medication at the time of cytopenia.
The therapeutic approach for patients with trilineage reconstitution failure after allogeneic HCT needs to be individualized. Our patient received daily intravenous administration of G-CSF when ANC decreased to below 1000/ml along with the management of underlying conditions. Overall, 20 of 43 patients (47%) with reconstitution failure recovered at least partially 8-323 days after the initial documentation of cytopenia. Out of those 20 patients, 12 recovered completely 120-938 days later (Figure 1 ). Multivariate analysis showed that the number of lineages involved in cytopenia was the only independent predictor for the recovery of cytopenia. The timing of failure (initial vs subsequent), presence of acute GVHD, and chimerism status at the onset of cytopenia did not show significant correlation with the recovery from cytopenia. Further studies with larger numbers of patients may uncover the other important predictors for the recovery.
The survival of patients who experience reconstitution failure is poor, with a median survival time of about 9 months. Obviously, recovery from the cytopenia was the most important determinant of the survival of patients with 5/20 patients vs. 20/23 patients without partial recovery dying. Most patients died of the underlying disease process. Four patients died of sepsis related to intractable cytopenia. The 11 patients in our series, who had no associated clinical conditions that could explain the cause of cytopenia, may be considered to be in a state of secondary graft failure in a traditional sense. These patients accounted for 26% of all patients with reconstitution failure and 7% of our study patients. Seven of 10 patients who were tested showed a mixed chimerism of recipient DNA of 5-75%, while three showed complete donor chimerism at the time of cytopenia. To develop an effective therapeutic strategy in this subgroup of patients, uniform diagnostic criteria of secondary graft failure need to be established. The role of hematopoietic chimerism assay as an aid in the diagnosis as well as in the prediction of response in this group of patients need to be established as well.
In conclusion, a significant proportion of patients (26%) experience trilineage reconstitution failure after allogeneic HCT, which was reversible at least partially in 47% of the patients. The number of lineages involved in the cytopenia was an independent variable that predicted recovery. Trilineage reconstitution failure needs to be analyzed systematically in the future studies, which may provide objective overall measures of the effectiveness of various methods of allogeneic HCT.
